|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000016706 |
|
Date of registration:
|
04/03/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis
|
|
Scientific title:
|
Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis - Efficacy of inhaled N-acetylcysteine in IPF |
|
Date of first enrolment:
|
2013/01/07 |
|
Target sample size:
|
25 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019377 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Ryo Okuda |
|
Address:
|
8-3-33 Kami-ochiai, Chuo-ku, Saitama, Japan
Japan |
|
Telephone:
|
048-852-1111 |
|
Email:
|
b980013@yahoo.co.jp |
|
Affiliation:
|
Saitama Red Cross Hospital Respiratory medicine |
|
|
Name:
|
Ryo Okuda |
|
Address:
|
8-3-33 Kami-ochiai, Chuo-ku, Saitama, Japan
Japan |
|
Telephone:
|
048-852-1111 |
|
Email:
|
b980013@yahoo.co.jp |
|
Affiliation:
|
Saitama Red Cross Hospital Respiratory medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: The exclusion of other clinically known causes of UIP such as drug-induced pneumonitis, collagen vascular diseases, and hypersensitivity pneumonitis.
Age minimum:
40years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Idiopathic pulmonary fibrosis
|
|
Intervention(s)
|
|
N-acetylcysteine was administered by inhalation at the dose of 352.4 mg b.i.d. via an ultrasonic nebulizer.
|
|
Primary Outcome(s)
|
|
An absolute change in FVC at week 26 after the initiation of N-acetylcysteine therapy.
|
|
Source(s) of Monetary Support
|
|
None
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|